Notice of AGM

RNS Number : 6129W

Novacyt S.A.

19 August 2020

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Notice of AGM

Paris, France and Camberley, UK - 19 August 2020 -   Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that its Annual General Meeting (AGM) will be held as a closed meeting at 2pm CEST/1pm BST on Tuesday 29 September. The AGM comprises both ordinary and extraordinary general meetings.

In accordance with precautionary measures put in place by the French Government due the COVID-19 pandemic, and with the health and safety of its shareholders and employees being a priority, the AGM will be held without the presence of shareholders.

The Notice of AGM and a Form of Proxy will be posted to shareholders in the week commencing 7 September 2020 and will also be available on the Company's website at this time. Shareholders are strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the Notice.

Shareholders will be able to view a live webcast of the AGM, details of which will be provided in the Notice of AGM. Following the AGM, a recording of the meeting will be available on the Company's website at www.novacyt.com .

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

[phone]

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

[phone]

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

[phone]

[e-mail] ;  [e-mail]

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

[phone]

[e-mail] / [e-mail]  

FTI Consulting (France)

Arnaud de Cheffontaines

[phone]

[e-mail]  

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests.  Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

 

END

 

 

NOALKLFFBVLBBBZ